Fed­er­al judge up­holds Cabome­tyx patent in Ex­elix­is' gener­ic bat­tle

A fed­er­al judge up­held a key patent on Ex­elix­is’ can­cer drug Cabome­tyx on Thurs­day, deal­ing a blow to MSN Lab­o­ra­to­ries’ po­ten­tial gener­ic ver­sion.

Ex­elix­is filed suit against MSN back in 2019, af­ter the lat­ter com­pa­ny sub­mit­ted an ab­bre­vi­at­ed new drug ap­pli­ca­tion (AN­DA) for its Cabome­tyx gener­ic. If MSN’s drug wins ap­proval, Ex­elix­is ar­gued in the ini­tial com­plaint that it would in­fringe on at least one or two claims of a patent dubbed ‘776, which ex­pires in 2030, ac­cord­ing to the FDA’s Or­ange Book.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER